Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809131 · ClinicalTrials.gov registry record · Phase 3
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,010
- Enrollment target
NCT02809131: Completed Phase 3 study, sponsored by Vanderbilt University Medical Center.
NCT02809131 is a Phase 3 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1,010 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02809131, a Phase 3 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,010 participants
- Enrollment target
Study Summary
The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or intravascular leads, have become increasingly prevalent, with the rate of growth in infections outpacing that of CIED procedures. The odds of both short term and long term mortality are at least doubled in patients who suffer CIED infections, and long term survival is particularly poor in women. Optimal strategies to prevent CIED infections in high-risk patients are largely unproven. However, recent observational studies of an antibiotic-coated envelope implanted at the time of CIED procedure have shown that this strategy is associated with a low incidence of CIED infections. Other interventions to prevent CIED infections, including the use of antibiotic irrigant used to wash the pocket during implantation and postoperative oral antibiotics, are commonly used but not supported by rigorous controlled studies. The Specific Aim of this study is to test the hypothesis that the use of the antibacterial envelope alone is noninferior to a strategy using the antibacterial envelope and intraoperative antibacterial irrigant and postoperative oral antibiotics for the reduction of cardiac implantable device infections in patients with ≥2 risk factors for infection.
Primary Outcome
The primary study endpoint will be the number of patients with CIED infection resulting in complete CIED system removal, antibiotic therapy in patients who are not candidates for system removal, or death due to CIED infection.
Interventions
- DRUG Saline
- DRUG polymixin/bacitracin
- DRUG cephalexin, or levofloxacin, or clindamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 3 |
What the finished NCT02809131 record still lists
NCT02809131 is an interventional study that assigns participants to a tested intervention. Its 1,010 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT02809131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02809131 about?
NCT02809131 is a clinical study titled "Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.". The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or intravascular leads, have become increasingly prevalent, with the rate of growth i...
What is the current status of trial NCT02809131?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,010 participants. The study started on 2016-04-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02809131?
The interventions under investigation include: Saline (DRUG), polymixin/bacitracin (DRUG), cephalexin, or levofloxacin, or clindamycin (DRUG).
Who is sponsoring clinical trial NCT02809131?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02809131's enrollment target sits among peer trials
1,010 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI